Published: 04/28/2020 21:33 GMT
CRISPR Therapeutics AG (CRSP) - Crispr Therapeutics Provides Business Update and Reports First Quarter 2020 Financial Results.
Crispr Therapeutics Ag - Cash and Cash Equivalents As of March 31, 2020, Were $889.7 Million.
Crispr Therapeutics Ag Qtrly Total Collaboration Revenue Was $0.2 Million Versus $0.3 Million.
Crispr Therapeutics Ag Qtrly Basic Loss per Share $1.15).
Crispr Therapeutics Ag - Enrollment Ongoing in Clinical Trials of Ctx001 for Patients With Severe Hemoglobinopathies.
Crispr Therapeutics Ag - Enrollment Ongoing in Clinical Trial of Ctx110, Targeting Cd19+ Malignancies.
Revenue is expected to be $3.02 Million
Adjusted EPS is expected to be -$1.06

Next Quarter Revenue Guidance is expected to be $3.27 Million
Next Quarter EPS Guidance is expected to be -$1.12

More details on our Analysts Page.



Source link